...
首页> 外文期刊>World Journal of Gastroenterology >Systemic immune responses to oral administration of recombinant attenuated Salmonella typhimurium expressing Helicobacter pylori urease in mice.
【24h】

Systemic immune responses to oral administration of recombinant attenuated Salmonella typhimurium expressing Helicobacter pylori urease in mice.

机译:对小鼠口服表达幽门螺杆菌脲酶的重组减毒鼠伤寒沙门氏菌的全身免疫反应。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To evaluate whether attenuated Salmonella typhimurium producing Helicobacter pylori (H pylori) urease subunit B (UreB) could induce systemic immune responses against H pylori infection. METHODS: Attenuated S. typhimurium SL3261 was used as a live carrier of plasmid pTC01-UreB, which encodes recombinant H pylori UreB protein. Balb/c mice were given oral immunization with two doses of SL3261/pTC01-UreB at a 3-wk interval. Twelve weeks after oral immunization of mice, serum IgG antibodies were evaluated by ELISA assay. Gamma interferon (IFN-gamma) and interleukin 10 (IL-10) in the supernatant of spleen cell culture were also assessed by ELISA. RESULTS: After oral immunization of mice, serum specific IgG antibodies against UreB in vaccine group were much higher than that in PBS and native Salmonella SL3261 control groups (A(450), 0.373+/-0.100 vs 0.053+/-0.022, 0.142+/-0.039, respectively, P<0.01). Moreover, IFN-gamma in vaccine group was on average 167.53+/-29.93 pg/mL, which showed a significant increase vs that of PBS control group (35.68+/-3.55 pg/mL, P<0.01). There was also a tremendous increase of IL-10 in vaccine group compared to PBS and SL3261 control groups (275.13+/-27.65 pg/mL vs 56.00+/-7.15 pg/mL, 68.02+/-15.03 pg/mL, respectively, P<0.01). In addition, no obvious side effects in mice and no change in gastric inflammation were observed. CONCLUSION: The multiple oral immunizations with the attenuated S. typhimurium expressing H pylori UreB could induce significant systemic immune responses, suggesting it may be used as oral vaccine against H pylori infection.
机译:目的:评估减毒鼠伤寒沙门氏菌产生的幽门螺杆菌(H pylori)脲酶B亚单位(UreB)是否可以诱导针对幽门螺杆菌感染的全身免疫反应。方法:使用减毒的鼠伤寒沙门氏菌SL3261作为质粒pTC01-UreB的活载体,该质粒编码重组幽门螺杆菌UreB蛋白。对Balb / c小鼠进行3周间隔两次口服SL3261 / pTC01-UreB的口服免疫。小鼠口服免疫后十二周,通过ELISA测定法评估血清IgG抗体。还通过ELISA评估了脾细胞培养上清液中的γ-干扰素(IFN-γ)和白介素10(IL-10)。结果:小鼠口服免疫后,疫苗组中针对UreB的血清特异性IgG抗体远高于PBS和天然沙门氏菌SL3261对照组(A(450),0.373 +/- 0.100 vs 0.053 +/- 0.022,0.142+分别为--0.039,P <0.01)。此外,疫苗组的IFN-γ平均为167.53 +/- 29.93 pg / mL,与PBS对照组相比有显着增加(35.68 +/- 3.55 pg / mL,P <0.01)。与PBS和SL3261对照组相比,疫苗组的IL-10含量也大大增加(分别为275.13 +/- 27.65 pg / mL和56.00 +/- 7.15 pg / mL,分别为68.02 +/- 15.03 pg / mL, P <0.01)。另外,没有观察到小鼠的明显副作用,也没有观察到胃炎症的变化。结论:减毒鼠伤寒沙门氏菌表达幽门螺杆菌UreB的多次口服免疫可诱导明显的全身免疫反应,提示其可作为抗幽门螺杆菌感染的口服疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号